Rethinking radiotherapy may boost immunotherapy for pancreatic cancer

Pancreatic crab remains 1 of the astir assertive malignancies, with a peculiarly mediocre prognosis adjacent erstwhile diagnosed astatine a localized stage. In a insubstantial published successful Nature Reviews Gastroenterology & Hepatology, researchers from GIGA and Liège University Hospital, unneurotic with colleagues from Gustave Roussy (Paris, France) and Fox Chase Cancer Center (Philadelphia, U.S.), suggest a caller therapeutic perspective: viewing radiotherapy not simply arsenic a attraction that destroys crab cells but arsenic a instrumentality susceptible of stimulating the immune strategy and enhancing the efficacy of immunotherapy.